bw 373u86 has been researched along with Adverse Drug Event in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ajello, CW; Barker, WM; Belanger, S; Brogdon, BL; Cassel, JA; Christ, DD; Chu, GH; DeHaven, RN; DeHaven-Hudkins, DL; Derelanko, MJ; Dolle, RE; Feschenko, MS; Graczyk, TM; Gu, M; Koblish, M; Kutz, S; Le Bourdonnec, B; Leister, LK; Little, PJ; Smith, SA; Tuthill, PA; Wiant, DD; Windh, RT | 1 |
1 other study(ies) available for bw 373u86 and Adverse Drug Event
| Article | Year |
|---|---|
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
Topics: Administration, Oral; Analgesics; Animals; Benzamides; Benzopyrans; Biological Availability; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Ether-A-Go-Go Potassium Channels; Humans; Maximum Tolerated Dose; Mice; Molecular Structure; Motor Activity; Pain; Pain Measurement; Rats; Receptors, Opioid, delta; Toxicity Tests | 2008 |